Morgan Stanley reiterates Overweight rating on Viking Therapeutic stock

Viking Therapeutics (VKTX) reported strong Phase 2 results for its oral weight loss drug VK2735, with the 120mg dose achieving 12.2% weight loss, surpassing the 8% efficacy threshold and supporting its potential for obesity maintenance. Despite these positive efficacy results, the stock experienced a significant decline due to noted higher gastrointestinal adverse event rates. However, multiple analysts, including Morgan Stanley, Jefferies, Stifel, BTIG, and H.C. Wainwright, reiterated Buy ratings, suggesting these tolerability issues are manageable through dose optimization and emphasizing the drug's competitive profile in the obesity market.

Analysis

Viking Therapeutics (VKTX) presents a classic case of positive clinical data meeting negative market sentiment. The company's Phase 2 trial for its oral weight loss drug, VK2735, demonstrated strong, dose-dependent efficacy, with the highest dose achieving a 12.2% average weight loss that surpasses the approximate 8% threshold for clinical significance. Despite these compelling results and a 30% stock gain over the past six months, the stock saw a significant decline post-announcement. This was driven by investor concerns over the drug's tolerability, specifically higher rates of gastrointestinal adverse events, which align its side-effect profile more closely with oral competitors. However, a strong consensus of Wall Street analysts, including Morgan Stanley, Jefferies, Stifel, and BTIG, have reiterated Buy or Overweight ratings with price targets ranging from $95.00 to $125.00, far above the current trading price of $24.64. Analysts broadly view the tolerability issues as a surmountable challenge that can be addressed through dose optimization or slower titration in future studies, which are slated to begin in Q3 2025. The data also supports a potential role for VK2735 as an obesity maintenance therapy, adding another layer to its long-term value proposition.

Key Decisions for Investors

• Investors should weigh the significant disconnect between the stock's current price ($24.64) and the bullish analyst consensus (price targets of $95-$125), which may represent a mispricing opportunity for those with a higher risk tolerance for clinical-stage biotechnology assets.
• The primary risk factor to monitor is the drug's tolerability profile; any future data or trial design updates that successfully mitigate the gastrointestinal side effects could serve as a major de-risking catalyst for the stock.
• Given the next clinical trial is not scheduled to commence until Q3 2025, this is a long-term catalyst play, requiring patience and an assessment of the company's competitive positioning in the dynamic obesity market.
• Consider the current market reaction as an indicator of high sensitivity to safety data, suggesting that any negative news from competitors' oral drugs could also create volatility for VKTX.